Clinical Trial of AVL-3288 in Schizophrenia Patients

Inclusion Criteria: * DSM-V diagnosis of schizophrenia or schizoaffective disorder * RBANS Total Scale Score \>62 * Willing to provide informed consent * Medically stable for study participation * Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks * Judged clinically not to be at significant suicide or violence risk Exclusion Criteria: * Substance abuse (excluding nicotine) within last 90 days * ECG abnormality that is clinically significant * Current clozapine use * Participation in a study of investigational medication/device within 4 weeks * Pregnancy, lactation, or lack of use of effective birth control * Active tobacco use * Presence or positive history of significant medical or neurological illness, including cardiac illness, WBC \<3500/mm3, absolute neutrophil count \<1500/mm3, ALT or AST values \>1.5 times upper limit of normal. Hemoglobin less than 130 g/L (13 g/dL) in males or 120 g/L (12 g/dL) in females or known HIV + * Contraindication to MRI scanning, including metal implants or claustrophobia * Medicinal patch, unless removed